» Authors » Anne-Marie Cumiskey

Anne-Marie Cumiskey

Explore the profile of Anne-Marie Cumiskey including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 13
Citations 255
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu J, Shao P, Guiadeen D, Krikorian A, Sun W, Deng Q, et al.
Bioorg Med Chem Lett . 2020 Nov; 32:127668. PMID: 33161125
Cholesteryl ester transfer protein (CETP) inhibitors reduce the transfer of cholesteryl esters from the high-density lipoprotein (HDL-C) to apolipoprotein such as VLDL/LDL, with exchange of triglycerides. Thus, this inhibition increases...
2.
McLaren D, Han S, Murphy B, Wilsie L, Stout S, Zhou H, et al.
Cell Metab . 2018 May; 27(6):1236-1248.e6. PMID: 29706567
Diacylglycerol acyltransferase 2 (DGAT2) catalyzes the final step in triglyceride (TG) synthesis and has been shown to play a role in regulating hepatic very-low-density lipoprotein (VLDL) production in rodents. To...
3.
More V, Lao J, McLaren D, Cumiskey A, Murphy B, Chen Y, et al.
PLoS One . 2017 Oct; 12(10):e0186586. PMID: 29065174
Lipid lowering properties of glucagon have been reported. Blocking glucagon signaling leads to rise in plasma LDL levels. Here, we demonstrate the lipid lowering effects of acute dosing with Glp1r/Gcgr...
4.
Wilson J, Kurukulasuriya R, Reibarkh M, Reiter M, Zwicker A, Zhao K, et al.
ACS Med Chem Lett . 2016 Mar; 7(3):261-5. PMID: 26985312
Using the collective body of known (CETP) inhibitors as inspiration for design, a structurally novel series of tetrahydroquinoxaline CETP inhibitors were discovered. An exemplar from this series, compound 5, displayed...
5.
McLaren D, Cardasis H, Stout S, Wang S, Mendoza V, Castro-Perez J, et al.
Anal Chem . 2013 May; 85(13):6287-94. PMID: 23668715
We have previously reported on a liquid chromatography-mass spectrometry method to determine the disposition of [(13)C18]-oleic acid following intravenous and oral administration in vivo. This approach has enabled us to...
6.
Yin W, Carballo-Jane E, McLaren D, Mendoza V, Gagen K, Geoghagen N, et al.
J Lipid Res . 2011 Oct; 53(1):51-65. PMID: 22021650
In an attempt to understand the applicability of various animal models to dyslipidemia in humans and to identify improved preclinical models for target discovery and validation for dyslipidemia, we measured...
7.
Smith C, Ali A, Hammond M, Li H, Lu Z, Napolitano J, et al.
J Med Chem . 2011 Jun; 54(13):4880-95. PMID: 21682257
The development of the structure-activity studies leading to the discovery of anacetrapib is described. These studies focused on varying the substitution of the oxazolidinone ring of the 5-aryloxazolidinone system. Specifically,...
8.
Tadin-Strapps M, Peterson L, Cumiskey A, Rosa R, Mendoza V, Castro-Perez J, et al.
J Lipid Res . 2011 Mar; 52(6):1084-1097. PMID: 21398511
Increased serum apolipoprotein (apo)B and associated LDL levels are well-correlated with an increased risk of coronary disease. ApoE⁻/⁻ and low density lipoprotein receptor (LDLr)⁻/⁻ mice have been extensively used for...
9.
Sweis R, Hunt J, Sinclair P, Chen Y, Eveland S, Guo Q, et al.
Bioorg Med Chem Lett . 2011 Mar; 21(9):2597-600. PMID: 21398121
The development of 2-phenylbenzoxazoles as inhibitors of cholesteryl ester transfer protein (CETP) is described. Efforts focused on finding suitable replacements for the central piperidine with the aim of reducing hERG...
10.
Sweis R, Hunt J, Kallashi F, Hammond M, Chen Y, Eveland S, et al.
Bioorg Med Chem Lett . 2010 Dec; 21(6):1890-5. PMID: 21147531
The development of 2-phenylbenzoxazoles as inhibitors of cholesteryl ester transfer protein (CETP) is described. Initial efforts aimed at engineering replacements for the aniline substructures in the benchmark molecule. Reversing the...